Application value of 18 F-FDG PET/CT in predicting EGFR mutation status in non-small cell lung cancer
10.3760/cma.j.issn.2095-2848.2019.10.012
- VernacularTitle:18 F-FDG PET/CT在非小细胞肺癌EGFR突变状态预测中的应用价值
- Author:
Guotao YIN
1
;
Wengui XU
;
Xiaofeng LI
Author Information
1. 天津医科大学肿瘤医院分子影像与核医学诊疗科、国家肿瘤临床医学研究中心、天津市肿瘤防治重点实验室、天津市恶性肿瘤临床医学研究中心 300060
- Keywords:
Carcinoma,non-small-cell lung;
Mutation;
Receptor,epidermal growth factor;
Positron-emission tomography;
Tomography,X-ray computed;
Deoxyglucose;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2019;39(10):623-626
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is a malignant tumor with the high morbidity and mortality in the world, and non-small cell lung cancer ( NSCLC) is the most common type. The emergence of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in recent years has provided new treatment option for NSCLC patients. The efficacy of EGFR-TKI is closely related to the EGFR mutation status, but the current detection methods for gene mutation have certain limitations. As a non-invasive method, 18F-fluorodeoxyglucose (FDG) PET/CT shows a certain potential in the detection of EGFR gene mutation status. In this paper, the re-cent research and progress of PET/CT in predicting the mutation status of EGFR gene are reviewed.
